Entasis Therapeutics (NASDAQ:ETTX) Target Raised by BMO Capital Markets to $7.00

StockMarketDaily.co reports: Entasis Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Entasis Therapeutics stock Target Raised by   BMO Capital Markets on 10/20/2021. In a note to investors, the firm issued a new target price of $7.00. The analysts previously had $5.00 target price.

View More Entasis Therapeutics (NASDAQ:ETTX) Target Raised by BMO Capital Markets to $7.00

Entasis Therapeutics (NASDAQ:ETTX) Target Raised by HC Wainwright – 4 stars to $6.00

StockMarketDaily.co reports: Entasis Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Entasis Therapeutics stock Target Raised by   HC Wainwright – 4 stars on 10/19/2021. In a note to investors, the firm issued a new target price of $6.00. The analysts previously had $5.00 target price.

View More Entasis Therapeutics (NASDAQ:ETTX) Target Raised by HC Wainwright – 4 stars to $6.00

Entasis Therapeutics (NASDAQ:ETTX) Downgraded by Zacks Investment Research to Sell

Entasis Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Entasis Therapeutics Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Entasis Therapeutics (NASDAQ:ETTX) Downgraded by Zacks Investment Research to Sell